Welcome

The Cochrane Schizophrenia Group (CSG) was formed in 1994. The CSG’s editorial base is located in Nottingham (UK). Our editors are based in Brazil, India, China, USA and Germany, as well as the UK, and our reviewers are based all over the world. The CSG’s editorial base in Nottingham is affiliated with The University of Nottingham's School of Community Health Sciences and, within that, the Division of Psychiatry. It also forms part of the Institute of Mental Health.

 The CSG is concerned with the evaluation of the prevention, treatment and rehabilitation of people with non-affective, functional, psychotic illnesses. The treatment of those with schizophrenia is a major focus of the Group but it is also concerned with the care of those suffering from unspecified 'chronic/severe' mental illnesses and non-organic, schizophrenia-like conditions fall under the Group's umbrella. In addition, the evaluation of care of those with the primary diagnosis of schizophrenia compounded by depression, substance misuse or specific problematic behaviours such as fire setting or aggression is relevant to this Group. Finally, evaluating the management of problems associated with interventions for schizophrenia or chronic/severe mental illnesses, such as the adverse effects of medication, is also within the Cochrane Schizophrenia Group's scope.

The work of the CSG focuses on two main areas. The first is the preparation, publication and maintenance of systematic reviews of the effects of interventions for schizophrenia. These reviews are published quarterly on The Cochrane Library, and are updated periodically to incorporate new research as it becomes available. The second is the development and maintenance of a specialised register of trials relevant to the scope of the group’s work.